A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel
Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/day, 400mg/day,
600mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without
Secondary Generalization
Not available
Phase 2
Currently not available on Sponsor Clinical Study Registry but will be included in the next stepwise expansion of the Registry's scope (by end of Q1 2015).

Analysis and Reporting Dataset is AD not ADaM

Datasets are available in English only

Study is not posted on ClinTrials Gov because it completed prior to registry reporting requirements
July 2014